Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial

被引：23

作者：

Emens, L. A. ^{[1
]}

Molinero, L. ^{[2
]}

Adams, S. ^{[3
]}

Rugo, H. S. ^{[4
]}

Schneeweiss, A. ^{[5
,6
]}

Dieras, V. ^{[7
]}

Iwata, H. ^{[8
]}

Barrios, C. H. ^{[9
]}

Nechaeva, M. ^{[10
]}

Winer, E. P. ^{[11
]}

Chang, C. W. ^{[12
]}

Chui, S. Y. ^{[13
]}

Schmid, P. ^{[14
]}

Loi, S. ^{[15
]}

机构：

[1] UPMC Hillman Canc Ctr, Med Hematol Oncol Dept, Pittsburgh, PA USA

[2] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA

[3] NYU, Sch Med, Langone Med Ctr, New York, NY USA

[4] UCSF Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA

[5] Univ Hosp, Div Gynecol Oncol, Heidelberg, Germany

[6] German Canc Res Ctr Heidelberg, Heidelberg, Germany

[7] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[8] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[9] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Ctr Pesquisa Clin, Porto Alegre, RS, Brazil

[10] Arkhangelsk Reg Clin Oncol Dispensary, Med Oncol, Arkhangelsk, Russia

[11] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[12] Genentech Inc, PHC & Early Dev Oncol Biostat, San Francisco, CA 94080 USA

[13] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[14] Queen Mary Univ London, Barts Canc Inst, London, England

[15] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.398

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

296P

引用

页码：S360 / S361

页数：2